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CLINICAL INVESTIGATION
Autoantibodies to lactoferrin and histone in systemic vasculitis
identified by anti-myeloperoxidase solid phase assays
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Autoantibodies to lactoferrin and histone in systemic vasculitis identi-
fied by anti-MPO solid phase assays. We aimed at confirming the antigen
specificity recognized by anti-neutrophil cytoplasm antibodies (ANCA)
in patients presenting systemic vasculitis with anti-myeloperoxidase
(MPO) activity on ELISA. Thirty-five consecutive patients with reac-
tivity in anti-MPO ELISA and systemic microscopic vasculitides were
tested in slot and Western blot analyses. Eleven of 35 sera exhibited
binding in Western blot studies with the MPO preparation used in the
ELISA: five sera bound at the size of MPO, but five sera reacted with
a 78 kD species (p78) co-purifying with MPO, and one serum blotted
both MPO and p78. Sequence analysis and antigen-specific assays
including Western blot studies showed that p78 is lactoferrin. All
anti-lactoferrin positive sera, but no anti-MPO positive sera, also
exhibited anti-nuclear binding on HEp2 cells with specificity for his-
tone. We concluded that: (a) a subgroup of patients presenting systemic
vasculitis with false anti-MPO reactivity on ELISA had anti-lactoferrin
antibodies; (b) anti-lactoferrin was associated with anti-nuclear activity
with specificity for histone; (c) these patients had systemic vasculitis
without histological evidence of immune complex deposition.
Circulating anti-neutrophil cytoplasm antibodies (ANCA) are
autoantibodies associated with small vessel vasculitis such as
Wegener's granulomatosis (WG) [1], microscopic polyarteritis
(MPA) [2], and a renal limited form of this disease previously
called "idiopathic rapidly progressive glomerulonephritis" [3].
Two patterns of antibody binding have been defined by indirect
immunofluorescence: a granular cytoplasmic feature (C-
ANCA) and a predominantly pen-nuclear pattern (P-ANCA).
C-ANCA mainly recognize a 29 kD proteinase termed protein-
ase3 (PR3) [4-6], and most P-ANCA sera bind to purified
preparations of myeloperoxidase (MPO) [3], but may recognize
lactoferrin (LF) [7, 8] or elastase [9].
Some correlation exists between antigen specificities for
ANCA and disease expression. For example, anti-PR3 antibod-
ies are mainly found in WG [10]. However, MPO auto-reactiv-
ity may be associated with kidney-limited as well as extensive
systemic vasculitis [3], or with other diseases including mixed
connective tissue disease and systemic lupus erythematosus
(SLE) [11]. In this study, we found that some sera considered
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anti-MPO positive on solid-phase assays reacted with LF,
contaminating the highly purified commercial MPO prepara-
tion. These patients also presented anti-nuclear reactivity with
specificity for histone and a widespread systemic vasculitis
different from classical SLE.
Methods
ANCA assays
Screening for ANCA. Initial sera were assayed for IgG
ANCA activity by solid-phase immunoassay (SPIA) with a
neutrophil extract preparation known to contain all the ANCA
autoantigens (ANCA SPIA) [2]. Specificity was confirmed by
indirect immunofluorescence (IIF) as described [12]. hF was
repeated for some sera on a MPO-deficient cell line (U937) [13].
An:igen-spec(flc assays. An anti-myeloperoxidase (anti-
MPO) radioimmunoassay [14] was adapted to an ELISA as
previously described [15], using the reference commercial pu-
rified preparation (Calbiochem, La Jolla, California, USA).
Anti-LF activity was also sought by ELISA as follows. In brief,
5 pg/nil LF (Sigma Chemical Co., St. Louis, Missouri, USA;
L0520) was coated onto microtiter plates in phosphate-buffered
saline (PBS) and blocked with 2% gelatin in PBS. Sera were
coated at 1:50 dilution in PBS containing 1% gelatin and 0.1%
Tween 20, and binding was detected with a goat anti-human
immunoglobulin linked to alkaline phosphatase (Sigma, A3150).
MPO slot blot
Purified MPO (Calbiochem) was blotted on nitrocellulose
membrane either in the native form (20 gIml, 1 to 2 gIslot in
borate-buffered saline, BBS) or denatured in 2% SDS at the
same concentration. Native lysozyme (25 g/ml) was used as a
control ligand. The nitrocellulose strips were blocked with
Tris-buffered saline Tween (TBST) containing 2% dried
skimmed milk (TBSTM), and incubated for three hours at room
temperature with the 35 test or 20 control sera diluted 1:20 in
TBSTM, or with polyclonal rabbit anti-human MPO (Dako
A398) diluted 1:1000, or with monoclonal mouse anti-human
MPO (Dako M748) diluted 1:500. After washing with TBSTM,
alkaline phosphatase-conjugated anti-human IgG (Sigma
A3150) diluted 1:2000, or anti-rabbit IgG (Serotec 2ABO2A)
diluted 1:1000, or anti-mouse IgG (Dako D3 14) diluted 1:200 in
TBSTM was added, and incubated for one hour. Binding was
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Fig. 1. A. Calbiochem MPO slot blot (1 iig/slot). A rabbit polyclonal anti-MPO reagent blotted MPO both in reducing and non-reducing conditions
(lane 1). Anti-MPO positive human sera blotted only MPO in non-reducing conditions (lanes 2 to 7). No binding was found with normal human
control sera (lanes 8 and 9). B. Calbiochem MPO slot blot (2 gIs1ot). A rabbit polyclonal anti-MPO reagent blotted MPO in reducing and
non-reducing conditions (lane 1), but a mouse monoclonal reagent (lane 2) and anti-MPO positive human sera (lanes 3 and 5) blotted only MPO
in non-reducing conditions. No binding was found with normal human control sera (lanes 4 and 6).
detected by adding alkaline phosphatase substrate (BCIP, 11.5, the nitrocellulose strips were blocked with TBSTM. The
Sigma B8503 and NBT, Sigma N6876). 35 test and 40 negative control human sera diluted 1:20 in
TBSTM, or the polyclonal rabbit anti-human MPO diluted
Western blot studies 1:1000, were then blotted for three hours at room temperature,
MPO Western blot. Purified MPO (Calbiochem) diluted at 200 and binding was detected as described above.
g/ml in BBS was further diluted 1:1 in Laemmli sample buffer LF Western blot. One to 2 g LF (Sigma L0520) was loaded
with or without 5% mercaptoethanol. Two hundred and fifty ng in each lane in a Laemmli system with transfer and blotting as
of boiled or unboiled MPO were loaded in each lane in a 12% above.
acrylamide separating gel with 4% acrylamide stacking gel
according to Laemmli [16], using a Mighty Small gel apparatus Patients
(Hoefer Scientific Instruments, San Francisco, California, Between October 1990 and February 1991, sera from 156
USA) at 30 mA. After transfer for 30 minutes at 500 mA in 10 patients were positive in the ANCA assay and with binding >
mM 3-cyclohexylamino-l-propanesulfonic acid (CAPS) pH 50% (normal range <16% of reference standards) or a strong
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FIg. 2. Western blot on Calbiochem MPO in
non-reducing conditions. Lanes 1 to 3 and 5
to 7 were blotted with anti-MPO positive sera,
lane 4 was blotted with a rabbit polyclonal
reagent, and lanes 8 to 10 with normal human
control sera. Anti-MPO positive but not
controls bound to 78 or 120 kD bands.
P-ANCA immunofluorescence pattern. When tested for anti-
MPO activity, 35 sera from 35 patients exhibited over 20%
binding in the MPO-specific assay (normal range <8%) and
were selected for the study.
Clinical details were requested retrospectively by question-
naire for all patients who had a positive Western blot. Organ
involvement and serological data were tabulated.
Controls groups included 50 patients with systemic lupus
erythematosus and 25 normal blood donors.
Preparation of highly purified MPO
Polymorphonuclear leukocytes from a patient with chronic
granulocytic leukemia were separated on a 2% methylcellulose
34% hypaque gradient, and MPO was separated as described
[17]. This MPO preparation was further purified on a cation
exchange column (MonoS, Phannacia) in 50 m Na acetate
buffer pH 5.2. Fractions were tested for MPO activity, and iron
content was estünated by comparison of absorbance at 280 and
470 jim as described [171. Commercial MPO, and MPO pre-
pared as above, were run in SDS-PAGE and transferred to
nitrocellulose. The strips were then either stained with
Coomassie blue or blotted by anti-MPO sera or the rabbit
polyclonal anti-MPO antibody. Two main bands were found in
both preparations, one running at 120 kD in non-reducing
conditions corresponding to the MPO tetramer (as shown by
running the samples in reducing conditions and Western blot-
ting), and one running at 78 kD in both reducing and non-
reducing conditions. Both bands were cut out of the gel and
electro-eluted over 24 hours. After vacuum drying, proteins
were precipitated in 20 volumes of absolute ethanol overnight at
+4°C. After centrifugation, the pellets were washed twice in
water and stored frozen at —20°C until use.
Cyanogen bromide digestion and peptide sequencing
Purified MPO and 78 kD proteins were dissolved in 70%
formic acid and treated with an excess of cyanogen bromide for
24 hours at room temperature. After vacuum drying, the
digestion products were washed twice in water before fraction-
ation by Tricine-SDS-PAGE according to the procedure of
Schägger and von Jagow [18]. This system allows an optimal
separation of 1 to 20 kD species. Proteins were transferred to
0.2 m polyvinylidenedifluoride (PVDF) membrane in CAPS,
pH 11.5, for 30 minutes at 500 mA [19]. Strips were stained in
0.1% Coomassie blue in 50% methanol. The N-terminal peptide
sequence of two fragments was determined as described else-
where [20].
Screening for anti-nuclear antibody activities
Samples producing a positive Western blot were tested for
anti-nuclear binding by hF on HEp2 cells. When positive, the
following anti-nuclear specificities were sought: double-
stranded DNA (ds-DNA) by ELISA (DNALISA, BMD,
France), Ro-SSA, La-SSB, Sm and RNP by immuno-diffusion
(Immuno-Concepts, Sacramento, California, USA) and histone
by ELISA (Biolab, Belgium).
Anti-lactoferrin ELISA in control groups
Fifty SLE patients with anti-dsDNA antibodies and 25 nor-
mal blood donors were tested in LF ELISA. Furthermore, the
last 1300 sera tested for ANCA were prospectively assayed in
both anti-LF and anti-MPO ELISA.
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positive anti-MPO/anti-LF sera and pooled human normal
control sera (diluted 1:50) was tested. (ii) An MPO concentra-
tion that corresponded to antigen limiting concentration in the
assay was chosen for coating new ELISA plates. The binding of
dilution curves of anti-MPO/anti-LF positive sera was tested.
(iii) For each sera, a concentration that corresponded to the
steep part of the dilution curve (that is, autoantibody limiting
concentration) was determined. The sera were then preincu-
bated at this autoantibody limiting concentration with either LF
(500 to 0.8 ng/ml) or an irrelevant protein (bovine hemoglobin,
500 nglml) in glass tubes for one hour at 37°C, before incubation
on MPO (0.25 g/ml) coated ELISA plates. Therefore, both the
antigen in the solid phase and the autoantibody available for
inhibition in the fluid phase were in limiting concentrations in
this inhibition study. Results were expressed as percentage of
inhibition calculated according to the following formula:
S/LF — C
%inhibition=1—
with S binding of test serum, S/LF = binding of test serum
after pre-incubation with LF and C = binding of pooled human
normal control sera at the same concentration.
Results
Anti-MPO assay and hF on alcohol-fixed neutrophils
The 35 tested sera had a mean anti-MPO binding of 68.7%
(range 110.1 to 20.4%). There were 33 P-ANCA and 2 C-ANCA
patterns on hF.
Slot blot studies
Fig. 3. Western blot on Calbiochem MPO in reducing conditions.
Lanes ito 3 and 5 to 7 were blotted with anti-MPO positive sera, lane
4 was blotted with a rabbit polyclonal reagent, and lanes 8 to 10 with
normal human control sera. Anti-MPO positive sera, which blotted at
120 kD in non-reducing conditions, bound at 58 and 72 kD in reducing
conditions. Sera which blotted at 78 kD still blotted at 78 kD in reducing
conditions. The rabbit anti-MPO polyclonal reagent bound an additional
band at 14 kD.
Cross inhibition studies
Anti-nuclear factor and anti-MPO cross-inhibition studies.
Inhibition of antinuclear activity was sought by preincubation
of test sera with LF in the fluid phase as described [21.
Anti-MPO binding inhibition by preincubation with LF in the
fluid phase. To confirm that anti-MPO binding on ELISA can be
due to anti-LF activity, anti-MPO binding inhibition studies
with LF were performed. A three-step experiment was done. (i)
MPO was coated at decreasing concentration (ranging from 2 to
0.0625 pg/ml) on ELISA plate. The binding of three double-
Sera (31 of 35) with greater than 30% binding in the anti-MPO
assay) were shown to blot native MPO (1 sg/slot). Only two
sera blotted denatured MPO at this low coating concentration
and such blotting was faint (Fig. 1A). Stronger blotting on
denatured MPO was observed when 2 sg were coated onto each
slot (Fig. lB). Therefore, increasing protein concentration
allowed blotting of anti-MPO antibodies on denatured MPO.
The polyclonal rabbit anti-human MPO blotted native and
denatured MPO at both coating concentrations, whereas the
monoclonal mouse anti-human MPO blotted only the native
form of MPO (Fig. 1B). None of the samples tested blotted
native lysozyme used as control. None of the 20 control sera
reacted with MPO.
Western blot studies
Non-reducing SDS-PAGE of unboiled MPO (Fig. 2). Five
anti-MPO sera were shown to blot a band at 120 kD correspond-
ing to the known size of denatured, non-reduced MPO. Five
other sera reacted with a 78 kD species (p78), therefore recog-
nizing a different protein co-purifying with MPO. One serum
reacted with both the MPO 120 kD species and p78. The rabbit
polyclonal anti-human MPO (Dako A398) blotted both MPO
and p78 as well as degradation products at 40 kD, as previously
shown [21]. No blotting was observed with the other 24 sera
with lower anti-MPO binding and the 40 normal controls (Fig.
2).
Reducing SDS-PAGE of unboiled MPO (Fig. 3). Sera react-
ing with the MPO 120 kD species in non-reducing conditions
<Unboiled> <Boiled>
Fig. 4. Western blot on Calbiochem MPO
after boiling in reducing conditions. Lanes 1
and 5 were blotted with the rabbit polyclonal
anti-MPO reagent, lanes 2 and 6 with an anti-
p78 positive serum, lanes 3 and 7 with an anti-
MPO positive serum and lanes 4 and 8 with a
normal human control serum. Reactivity to
p78 was lost after the MPO preparation was
boiled.
Fragment 1: A—P—N--E—A—V—V—X—S—M—D—K—V-L—L
LF: A—M—A—P—N—H—A—V—V—S—R—M—D—K—V—E—R—L—K—Q—V-L—L—H—Q—Q—A--K—F—G—R—N
613 642
Fragment 2: D—K—V—E—T--L—K—Q—V—L—L—T—Q—Q—A—K—F
reacted with 58 and 72 kD bands corresponding to the size of
the MPO heavy chain and hemi-peroxidase (one heavy chain of
MPO bound to one light chain since total reduction was not
obtained without boiling the MPO preparation). Sera reacting
with p78 in non-reducing conditions still reacted at 78 kD in
reducing conditions. The rabbit polyclonal anti-human MPO
(Dako A398) blotted both MPO heavy (58 kD) and light chain
(14 kD) as well as p78 (Fig. 3).
Reducing SDS-PAGE of boiled MPO (Fig. 4). After boiling of
Calbiochem MPO, reactivity to p78 was lost (Fig. 4). Further-
more, total reduction of MPO and hemi-peroxidase was ob-
tained, and anti-MPO positive sera reacted only with the MPO
heavy chain (58 lcD) (Fig. 4). The rabbit polyclonal anti-MPO
reagent blotted both MPO light (14 kD) and heavy chains (58
lcD) as well as p78 and heat degradation products of MPO (Fig.
4), as previously shown [211.
Sequencing of p78 cyanogen bromide digestion products
The purity of p78 and MPO fractions after electro-elution was
assessed by Coomassie staining and Western blot analysis (data
not shown). The CNBr digestion products of MPO and p78
were separated by Tris-SDS-PAGE according to the method of
Schagger and von Jagow [18], and different digestion profiles
were found. Sequence analysis of p78 digestion products
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Table 1. Sequences of syanogen bromide digestion products of p78
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showed strong sequence homology to human lactoferrin (Table
1).
Lactoferrin ELISA and Western blot
The six sera with anti-p78 positivity (5 anti-p78, 1 double
positive anti-p78 and anti-MPO) were shown to bind in LF
ELISA.
This LF preparation was shown to be free of MPO, since
anti-MPO monoclonals are bound in MPO but not in LF
Western blot studies (M. Audrain, VLM Esnault, manuscript
submitted for publication).
Specificity was confirmed in LF Western blot studies since
reactivity was observed at 78 kD the size of LF (data not
shown).
hF on U937 and HEp2 cells
U937 cell. The five anti-p78 positive sera were tested for hF
on a MPO-deficient cell line (U937). The immunofluorescence
pattern on U937 was nuclear and not pen-nuclear (Fig. 5A).
HEp2 cell. All sera with anti-p78 reactivity, but no truly
anti-MPO positive sera, were shown to produce positive hF on
HEp2 cells with a homogeneous pattern (Fig. 5B).
Anti-nuclear antibody specficities
Anti-nuclear specificity was searched for in five of the six
anti-lactoferrin positive sera. All sera exhibited anti-histone
reactivity and no anti-dsDNA, anti-Ro/SSA, anti-LaJSSB,
anti-Sm or anti-RNP activity.
Anti-nuclear factor and anti-MPO cross inhibition studies
Inhibition of the binding of anti-p78 positive sera to HEp2
cells by preincubation with MPO in liquid phase was sought, as
described [2]. No inhibition was observed. Similar preincuba-
tion with lactoferrin also failed to alter the binding of anti-p78
positive sera to HEp2 cells.
Anti-MPO binding inhibition by preincubation with LF in the
fluid phase
The antigen limiting concentration chosen was 0.25 p.g/ml
(Fig. 6). One hundred percent inhibition of the anti-MPO
binding after preincubation of the three anti-p78 positive sera
with LF was observed (Fig. 7).
Some inhibition of the anti-MPO binding of 2/3 anti-MPO
positive/anti-LF negative sera was also observed after LF
preincubation. However, this was only possible at high LF
concentration and 100% inhibition was not obtained (Fig. 7).
This suggested a low affinity (probably nonspecific) interaction.
Clinical correlations
Clinical details were requested on all 11 patients whose sera
gave a positive Western blot. Despite repeated requests, only
Esnault et al: Anti-MPO, anti-LF and anti-his tone antibodies 159
0.0625 0.125 025 0.5 1.0 2.0
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Fig. 6. Influence of MPO concentration on anti-p 78 positive sera
binding. LFI, LF2 and LF3 are 3 anti-LF positive sera (diluted 1:50). C
is pooled human normal control sera (diluted 1:50).
eight replies were obtained (Table 2), making interpretation
difficult. However, three out of the five anti-LF positive pa-
tients had widespread organ involvement. Careful examination
of the biopsy specimens showed that none of the patients with
both anti-LF and anti-nuclear reactivity had the classical SLE
immune complex deposition in the kidneys. Two of these
patients had hydralazin-induced systemic vasculitis.
Screening of SLE and control groups for anti-LF antibodies
Three of 50 SLE patients with anti-dsDNA antibodies had
anti-LF antibodies, including one patient with anti-histone
activity. They also showed activity in anti-MPO ELISA.
The 25 normal blood donors had no anti-LF antibodies.
Among the last 1300 sera tested for ANCA, three had anti-LF
activity. They also exhibited reactivity in anti-MPO ELISA.
The first patient was one of the 50 SLE patients tested for
ANCA, and had anti-dsDNA, anti-RNP and anti-histone anti-
bodies. The second patient had rheumatoid arthritis and no
anti-histone antibodies. The third had ulcerative colitis and no
anti-histone activity.
Discussion
In this study, we describe six patients whose anti-lactoferrin
activity was originally detected by a standardized MPO assay
using the Calbiochem preparation. One of these patients' serum
bound denatured MPO in Western blot studies, which is indic-
ative of very strong, specific anti-MPO activity. The other
anti-LF positive sera had no anti-MPO antibodies as shown by
inhibition of anti-MPO binding after preincubation with LF in
the liquid phase. All of these patients with anti-LF antibodies
also had anti-nuclear antibodies with specificity for histone.
These anti-nuclear antibodies were a distinct, as opposed to a
cross reactive, population since cross inhibition studies were
negative.
Anti-MPO antibodies have been reported in patients present-
ing SLE [11, 22], rheumatoid vasculitis [22], and hydralazin-
induced systemic vasculitis. However, these data were not
confirmed in antigen-specific sandwich solid-phase assays [23].
More recently, anti-LF antibodies were reported in SLE [24]
and rheumatoid vasculitis [8]. We suggest that early workers
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might have been misled by LF contamination in MPO ELISA.
The patients in our study, selected from a group of individuals
presenting systemic vasculitides, had both anti-LF and anti-
histone antibodies but no anti-dsDNA and no immune complex
deposition in the kidneys. Therefore, they may represent a
syndrome overlapping between SLE and systemic vasculitis
closer to the vasculitic entity, contrary to patients with anti-
dsDNA and anti-LF antibodies who were classified as SLE.
Other diseases occasionally associated with anti-LF antibodies
include rheumatoid arthritis and ulcerative colitis. In the last
1300 consecutive sera tested for ANCA, only three anti-LF
positivity were found (one SLE, one rheumatoid arthritis, and
one ulcerative colitis patient).
We showed that the Calbiochem MPO preparation is not pure
since it contains at least two antigens recognized by ANCA in
sufficient amounts for ELISA detection. The amount of LF in
this preparation is small as shown by the faint Coomassie stain
in SDS-PAGE in our working conditions. However, it seems to
retain more antigenicity than MPO in denaturing conditions,
since it gave strong Western blotting.
We also showed that anti-MPO antibodies recognize a partly
conformational epitope. When slot blots on native and dena-
tured commercial MPO were compared, stronger blotting was
3
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Fig. 7. Anti-MPO binding inhibition by preincubation with LF in the
fluid phase. The 3 anti-LF positive sera are LF1 (diluted 1:80), LF2
(1:40) and LF3 (1:80). The 3 anti-MPO positive sera are MPOI (1:160),
MPO2 (1:160) and MPO3 (1:160).
Table 2. Clinical features of the 11 patients whose sera gave positive
Western blot on Calbiochem MPO
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observed on native than on denatured MPO. When the MPO
concentration was increased in Western blot studies, only 6 of
35 sera demonstrated convincing binding to denatured MPO (5
anti-MPO, 1 double positive anti-MPO and anti-LF). Further-
more, the epitope on LF but not on MPO was heat-sensitive.
Reactivity against more than one antigen is increasingly
apparent in ANCA-associated vasculitis. Jayne et al reported
patients with both ANCA and antiglomerular basement mem-
brane antibodies [25], and it was suggested that ANCA speci-
ficity in this subgroup is usually to MPO [26]. In this paper, we
reported patients with anti-nuclear antibodies and ANCA reac-
tivity against LF, including one with reactivity against at least
two constituents of the cytoplasm of the neutrophil. It is unclear
at present why these multiple reactivities exist, but these
patients may offer further clues to the mechanisms underlying
these diseases, particularly if it is confirmed that the autoanti-
body profile correlates with the pattern of clinical presentation.
Prospective studies involving a greater number of patients and
using truly antigen-specific assays are required to elucidate the
relationship between serological results and clinical presenta-
tion.
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